- 01/06/2020
- FYCOMPA? FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA
- 12/23/2019
- U.S. FDA APPROVES EISAI’S DAYVIGO? (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTS
- 12/09/2019
- Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- 12/05/2019
- EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN?) AT 42ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
- 12/02/2019
- EISAI TO PRESENT LATEST DATA ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT 12TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE
- 12/02/2019
- ADDITIONAL INDICATION FOR LENVIMA? (LENVATINIB) FOR DIFFERENTIATED THYROID CANCER ACCEPTED IN CHINA
- 12/02/2019
- Eisai China Inc. is certified as the “Top Employers China 2020”
- 12/01/2019
- Launch Meeting of the Third-Generation Antiepileptic Drug of Fycompa (Perampanel) in China
- 11/26/2019
- Eisai China Pharmaceutical Co., Ltd. Carried out Scholarships and Grants Program in Peking University Health Science Center for 8 Consecutive Years
- 11/26/2019
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 73RD AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
